Ovarian Cancer Immunotherapy
Samir A. Farghaly
Oxford University Press, Sep 28, 2018 - Medical - 272 pages
Ovarian Cancer Immunotherapy provides a broad overview of several aspects of basic sciences, and clinical and therapeutic aspects of immunotherapy for ovarian cancer, as well as state-of-the-art information on molecular genetics and biology. Chapters are written by a team of expert contributors from around the world and explore topics such as antibody therapeutics for ovarian carcinoma, emerging serum biomarkers, ovarian cancer immunity, adoptive cell immunotherapy, the biology of dendritic cells, the role of growth factors, and more. Readers will also gain a better understanding of the molecular and cellular events that underlie ovarian cancer immunology. This book is an ideal resource for clinicians, basic medical scientists, graduate basic medical science students, and medical students caring for patients with ovarian cancer, including attending surgeons and physicians, and clinical fellows and residents in the disciplines of gynecologic oncology, medical oncology, and surgical oncology.
What people are saying - Write a review
We haven't found any reviews in the usual places.
1 Antibody Therapeutics for Ovarian Carcinoma and Translation to the Clinic
2 Biological Aspects and Clinical Applications of Serum Biomarkers in Ovarian Cancer
How Does Immune Suppression Grow Cancer?
4 Ovarian Tumor Microenvironment and Innate Immune Recognition
5 Adoptive Cell Immunotherapy for Epithelial Ovarian Cancer
6 AntibodyBased Therapy for Ovarian Cancer
7 EpitopePeptideBased Monoclonal Antibodies for Immunotherapy of Ovarian Cancer
8 Dendritic Cell Vaccine Therapy for Ovarian Cancer
9 Heat Shock Protein Vaccine Therapy for Ovarian Cancer
10 PD1PDL1 Inhibitors as Immunotherapy for Ovarian Cancer
11 Growth Factors and Their Corresponding Receptors as Targets for Ovarian Cancer Therapy
12 Unique Challenges Facing Immunotherapy of Metastatic Ovarian Cancer
13 Clinical Trials of Ovarian Cancer Immunotherapy and Future Directions
Other editions - View all
activation anti-tumor antigen apoptosis ascites associated autologous bevacizumab binding Biol biomarkers carboplatin catumaxomab CD8+ T cells checkpoint chemotherapy Clin Cancer Res Clin Oncol clinical trials correlates cytokines cytotoxic DC vaccine dendritic cells disease effector endothelial epithelial ovarian cancer farletuzumab folate function gene GnRH growth factor Gynecol Oncol I/II immune cells immune response immune suppressive immune system Immunol immunological immunotherapy induced infiltration inhibit inhibitors ipilimumab ligands lymphocytes macrophages malignant marker mediated melanoma mesothelin metastatic MHC class miRNA molecules monoclonal antibodies mutations Nivolumab NK cells ovarian cancer cells ovarian cancer patients ovarian carcinoma ovarian tumors overall survival overexpressed paclitaxel pathway patients with advanced PD-L1 expression PDGFB Pembrolizumab peptide peritoneal Phase I trial prognostic proliferation proteins receptor recurrent regulatory T cells role serous ovarian serum signaling solid tumors specific stroma T-cell target therapeutic therapy tion tissues treatment Treg tumor antigens tumor cells tumor microenvironment tumor-infiltrating vaccine VEGF vivo